Enhancing Monoclonal Antibody Production: Advanced Downstream Purification Strategies

Downstream processing plays a critical role in delivering safe, high-quality monoclonal antibody therapies, yet persistent bottlenecks can limit capacity, increase costs, and delay time to market. Challenges such as low binding capacity, lengthy processing times, contamination risks, scalability constraints, and high resource use require a coordinated approach to optimization. High-capacity chromatography resins, continuous processing, buffer concentrates, single-use systems, automation, and sustainable practices can help manufacturers improve yield and product quality while reducing labor, facility footprint, consumable costs, and waste. Economic modeling using BioSolve Process™ demonstrates how these strategies can support more efficient and sustainable downstream manufacturing without compromising performance.

Access the full white paper to identify practical opportunities for improving mAb production.